
Loading, please wait...

Loading, please wait...

Researchers have successfully completed the first in vivo pharmacokinetic evaluation of 3D-printed veterinary formulations, specifically targeting canine heart failure management. This clinical trial utilized semisolid extrusion (SSE) to create 2.5 mg pimobendan (PBD) tablets, referred to as 'printlets.' These custom-made dosages offer a potential solution to the limitations of mass-produced veterinary medications. Frequently, commercial formulations lack dose flexibility and present sizing issues that complicate long-term treatment for smaller patients.
The study compared these innovative printlets against the established commercial formulation, Vetmedin, in healthy Beagle dogs. Scientists analyzed both formulations for weight, drug content, and in vitro dissolution before oral administration. To ensure accuracy, the team quantified plasma PBD concentrations using LC-MS/MS and determined pharmacokinetic parameters through non-compartmental analysis. While both formulations were safely tolerated without adverse effects, the 3D-printed veterinary formulations exhibited a distinct sustained release profile. This variation in absorption underscores the ability of digital manufacturing to modulate how a patient processes medication.
Digital manufacturing provides several advantages for modern veterinary practice. Firstly, SSE 3D printing allows for precise dosing, which is vital for managing chronic conditions like heart failure where titration is key. Secondly, the technology enables the creation of chewable, palatable tablets that can improve patient adherence. Furthermore, the ability to print medications on-demand helps clinicians adapt therapy to the evolving physiological needs of the patient. Consequently, this study serves as a critical proof-of-concept for the wider adoption of 3D printing in pharmacy settings.
Semisolid extrusion is a specialized 3D printing technique that uses medicinal gels or pastes to construct dosage forms layer-by-layer. Because it operates at lower temperatures, it is highly suitable for drugs that are sensitive to heat.
Unlike traditional mass-produced tablets, 3D-printed versions allow for highly customizable dosages and varied release profiles. This flexibility is essential for personalized medicine, especially when standard tablet sizes do not meet a specific patient's weight or metabolic requirements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical or veterinary advice. Refer to the latest local and national guidelines for clinical practice.
References
Leão J et al. From prototype to veterinary patient: a pharmacokinetic clinical trial of 3D-printed pimobendan tablets in beagle dogs. Drug Deliv Transl Res. 2026 May 25. doi: 10.1007/s13346-026-02156-z. PMID: 42184094.
Zhang B, et al. An investigation into the effects of ink formulations of semi-solid extrusion 3D printing on the performance of printed solid dosage forms. RSC Pharmaceutics. 2023.
CurifyLabs. A new technology brings 3D-printed compounded medications to the veterinary space. dvm360. 2025.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A pioneering study in Beagle dogs evaluates 3D-printed pimobendan tablets, demonstrating the potential for personalized drug delivery in veterinary medicine...
3 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today